Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Article in Nature Communications (February 2024)
The most recent citing publications are shown below. View all 32 publications that cite this research output on Dimensions.
HGF/c-Met/β1-integrin signalling axis induces tunneling nanotubes in A549 lung adenocarcinoma cells
Article in Life Science Alliance (August 2023)
Met-Signaling Controls Dendritic Cell Migration in Skin by Regulating Podosome Formation and Function
Article in Journal of Investigative Dermatology (February 2023)